Abstract In the last years there is an increasing trend towards
personalized medicine for patients with asthma.  is is due to the availability of novel speci c thera-pies.  ese new compounds are supposed to be used in well-de ned patient groups, which are likely to respond to these interventions. In addition to already used anti-IgE, novel monoclonal antibodies such as anti-IL-5 and anti-IL-13 are becoming avail-able. Currently clinical trials are ongoing to identify which patient population will respond to these novel therapies.